What EU Expansion Means for the Pharma Industry
The impact on the pharmaceutical industry of EU expansion in 2004 remains unclear. It may be an opportunity to drive growth in Europe to levels that could potentially rival the US, or it could result in increases to parallel trade, further lowering competitiveness and drug prices in Europe. IMS consultant Janice Haigh assesses the likelihood of both potential outcomes.
You may also be interested in...
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.
COVID-19 has triggered a dramatic shift toward virtual consultations and telemedicine, encouraged by more relaxed regulations and payer support.
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.